Katina Dorton - 02 Jun 2026 Form 4 Insider Report for Keenova Therapeutics plc

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 02 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Jun 2026, 16:12:26 UTC
Prior SEC filing: 22 May 2026
Next SEC filing: 10 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Mark Tyndall, Attorney-in-Fact

Key filing fact

Katina Dorton filed Form 4 for Keenova Therapeutics plc on 04 Jun 2026.

Key facts

This page summarizes Katina Dorton's Form 4 filing for Keenova Therapeutics plc.
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 Jun 2026, 16:12.

Change

Previous filing in this sequence was filed on 22 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001617541 Primary reporting owner

Dorton Katina

Relationship: Director
Address: 440 ROUTE 22 EAST, SUITE 302, BRIDGEWATER
Signature: /s/ Mark Tyndall, Attorney-in-Fact
Signature date: 04 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

No ticker transaction

Ordinary Shares

Options Exercise

Transaction value
Shares: +4,882
Change %: +195%
Price
Shares after: 7,387
Date: 02 Jun 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

No ticker transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -4,882
Change %: -15%
Price: $0.000000^*
Shares after: 27,000
Date: 02 Jun 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 4,882
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU.

Footnote F2

The RSUs, which were granted on August 14, 2025, vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders.

SEC remarks

This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.